{"product_id":"bway-ansoff-analysis","title":"(BWAY) BrainsWay Ltd. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BrainsWay Ltd. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help you assess strategic priorities and investment angles; the page shows a genuine preview\/sample of the analysis so you can inspect format and insight before buying. Purchase the full version to get the complete, ready-to-use company-specific Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS psychiatry-center adoption of dTMS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay’s U.S. market penetration is about getting more use from existing psychiatry sites, not changing the device. In clinics already treating 6 relevant disorders—MDD, anxious depression, OCD, PTSD, bipolar disorder, and smoking addiction—every added patient per site lifts dTMS utilization and revenue. This is the cheapest Ansoff move because the platform is already cleared and sold in the United States.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital account expansion in existing geographies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. can deepen penetration by adding psychiatry, neurology, and other departments in existing U.S., European, and Israeli hospital systems, using the same installed platform and clinical workflow. This keeps selling costs low and expands use inside accounts already trained on the system. The lever is more sites per health system, not new geographies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCondition-breadth selling within one platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay’s dTMS platform can be sold across several conditions, so one installed system can serve depression, OCD, and smoking cessation, while clinical work extends into PTSD and schizophrenia. That broad indication mix lifts chair utilization and spreads revenue across more patient pools. It also lowers reliance on any single diagnosis, which makes the model less exposed to reimbursement or demand shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMedical-professional referral growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s medical-professional referral growth depends on turning more clinicians into active referrers for existing treatment centers. That lifts treatment volume inside the current footprint, so market penetration can rise without opening new sites. In Ansoff terms, this is deeper use of the current market, not geographic expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore clinician awareness\u003c\/li\u003e\n\u003cli\u003eMore referrals to existing centers\u003c\/li\u003e\n\u003cli\u003eHigher utilization, no new geography\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor BrainsWay Ltd., this can improve revenue per installed center and support steadier demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInstalled-base utilization in current sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay Ltd. can lift revenue from its installed base by pushing higher patient throughput, broader indication use, and tighter clinic scheduling at sites already running dTMS. This is the cleanest market-penetration lever because it adds sales without adding new system installs. Every extra treatment slot at an active site improves yield from the current base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore visits per site\u003c\/li\u003e\n\u003cli\u003eMore indications treated\u003c\/li\u003e\n\u003cli\u003eHigher chair-time density\u003c\/li\u003e\n\u003cli\u003eNo new install needed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrainsWay’s Cheapest Growth Move: More Revenue From the Same Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s market penetration case is simple: grow use inside the current installed base, not into new markets. One dTMS system can treat 6 disorders already, so more referrals, more visits, and tighter scheduling lift revenue per center without new installs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLever\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003ePenetration effect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndications\u003c\/td\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003ctd\u003eMore patient pools per site\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003e1 dTMS system\u003c\/td\u003e\n\u003ctd\u003eHigher chair-time use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite focus\u003c\/td\u003e\n\u003ctd\u003eExisting centers\u003c\/td\u003e\n\u003ctd\u003eLower selling cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThis makes market penetration the cheapest Ansoff move for BrainsWay Ltd. because it adds volume from the same footprint, same workflow, and same cleared device.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing BrainsWay Ltd.’s growth strategy across products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps BrainsWay Ltd. quickly map growth options and remove expansion uncertainty with a clear Ansoff snapshot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of primary sources to validate BrainsWay Ltd. growth paths in Ansoff Matrix analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader European rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay already sells dTMS in Europe, so this is market development, not a new product launch. The next step is to enter more of the 27 European Union healthcare systems and nearby markets with the same device, which widens reach without changing the core platform. If reimbursement and clinic adoption scale, each new country can add incremental recurring treatment demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeeper international expansion outside the US and Europe\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay’s deeper push into countries beyond the US, Europe, and Israel is pure market development: the dTMS therapy stays the same, only the addressable market changes. That fits non-invasive neurostimulation demand in new health systems, where adoption can scale without new clinical positioning. In 2025, the key upside is more installed-use potential from the same cleared platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael-wide institutional reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay is headquartered in Jerusalem, and Israel-wide institutional reach fits a market-development move: expand the same Deep TMS platform from a few reference centers into more hospitals and medical centers across the country. That broadens the customer base without changing the core product, lowering rollout friction and lifting utilization across an existing local market. The upside is more clinic accounts, more treated patients, and stronger national visibility for the platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeurology and rehabilitation clinic entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay’s deep TMS can move from psychiatry into neurology and rehab clinics, because it already fits conditions like Parkinson’s, multiple sclerosis, Alzheimer’s, and post-stroke recovery. This is a new market for the same product: the World Health Organization says over 55 million people live with dementia, and stroke affects about 15 million people each year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew buyers: neurology and rehab centers\u003c\/li\u003e\n\u003cli\u003eSame device, new care setting\u003c\/li\u003e\n\u003cli\u003eTargets stroke, MS, Parkinson’s, Alzheimer’s\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-psychiatric care pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay Ltd. can use non-psychiatric care pathways to reach pain clinics and neurorehab units without changing the Deep TMS platform. That matters because its cleared use base already spans more than psychiatry, including chronic pain and neurologic recovery settings. One device, more buying centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands demand beyond mental-health-only sites\u003c\/li\u003e\n\u003cli\u003eTargets chronic pain and rehab budgets\u003c\/li\u003e\n\u003cli\u003eKeeps sales tied to the same platform\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrainsWay Expands Deep TMS Reach Across Europe and New Care Settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s market development is widening Deep TMS use into more countries and care settings without changing the device. The same platform can reach more of the 27 EU health systems and add neurology, rehab, and pain clinics, where WHO says dementia affects 55 million people and stroke hits 15 million yearly. More sites mean more patient volume from one cleared product.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU reach\u003c\/td\u003e\n\u003ctd\u003e27 systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDementia\u003c\/td\u003e\n\u003ctd\u003e55M people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStroke\u003c\/td\u003e\n\u003ctd\u003e15M cases\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eBrainsWay Ltd. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual BrainsWay Ltd. Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality, structured growth options, and clear strategic recommendations tailored to the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew indication protocols on dTMS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd. can use product development by adding new dTMS protocols to its installed base, so the same clinics treat more conditions. By 2025, the platform already supported FDA-cleared use in major areas like OCD and smoking cessation, and each added indication can lift device utilization without needing new hardware. \u003c\/p\u003e\n\u003cp\u003eThat matters because protocol expansion turns one system into a broader clinical menu, which can deepen recurring treatment volume and support higher revenue per site. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurological-use protocols for existing sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s neurological-use protocols for Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson’s disease are product development, not market entry, because they are new protocols sold through existing hospital and medical-center ties. That matters in a market where one added protocol can expand use without rebuilding distribution.\u003c\/p\u003e\n\u003cp\u003eThe logic is clear: same sites, new clinical use cases.\u003c\/p\u003e\n\u003cp\u003eFor BrainsWay Ltd., this can lift revenue per account and deepen site penetration while keeping selling costs tied to an installed base rather than new customer acquisition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized treatment settings and accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay can add site-level workflow tools and treatment accessories to its neurostimulation platform to deepen use at existing clinics and hospitals, which is classic product development. This fits the company’s installed base first, so adoption can rise without a new geography push. In FY2025\/FY2026, tie this to utilization, repeat sessions, and lower setup time.\u003c\/p\u003e\n\u003cp\u003eThat matters because BrainsWay’s core growth engine is already tied to provider adoption, so accessories that make treatment easier can lift seat usage and stickiness. A single software or hardware add-on can expand value per site faster than opening new markets. If each center treats more patients per day, revenue can scale with little extra sales cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform generation upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay’s platform generation upgrades are a product move in an existing market: it can refresh dTMS hardware and software without changing its core therapy category. In 2025, that fits a company still scaling recurring use across psychiatry and neurology sites, where better usability can lift adoption and treatment flow.\u003c\/p\u003e\n\u003cp\u003eExisting customers should see faster setup, simpler session management, and easier workflow control, which can support retention and upgrades. This matters because BrainsWay’s model depends on installed systems and repeat clinical use, not a new market entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame dTMS category\u003c\/li\u003e\n\u003cli\u003eBetter clinic usability\u003c\/li\u003e\n\u003cli\u003eStronger treatment management\u003c\/li\u003e\n\u003cli\u003eUpgrade-driven growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroader multi-condition treatment offering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay’s Deep TMS already spans 4 FDA-cleared indications, including major depressive disorder, OCD, smoking addiction, and anxious depression. Packaging these uses into one platform lets current clinics standardize on one device, one training path, and one service contract. That is classic product development: more value from the same installed base.\u003c\/p\u003e\n\u003cp\u003eThe move also raises wallet share because a clinic treating 2 or more conditions can keep patients inside the BrainsWay system instead of buying separate tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 cleared uses, one platform\u003c\/li\u003e\n\u003cli\u003eHigher standardization for clinics\u003c\/li\u003e\n\u003cli\u003eMore reasons to stay with BrainsWay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrainsWay Grows by Adding More Uses to the Same Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduct development for BrainsWay Ltd. means adding new Deep TMS protocols and workflow upgrades for the same clinic base. In FY2025, the platform already had 4 FDA-cleared uses, so each new protocol can raise utilization and revenue per site without new hardware. Same customers, more clinical uses.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA-cleared uses\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth lever\u003c\/td\u003e\n\u003ctd\u003eNew protocols\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue effect\u003c\/td\u003e\n\u003ctd\u003eHigher site use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePsychiatry-to-neurology revenue shift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay already serves both mental health and neurological use cases, so psychiatry-to-neurology diversification can build a second revenue engine instead of leaning mainly on depression demand. Its global reach across 60+ countries gives it a ready channel to sell rehabilitation and neurology systems faster. That shift can reduce concentration risk and widen the addressable market beyond psychiatry alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChronic-pain care expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChronic pain is already in BrainsWay Ltd.’s condition set, so packaging it as a separate line widens demand beyond psychiatric clinics. In the U.S., chronic pain affects about 51 million adults, so the buyer pool is much broader than office-based psychiatry. That shift can pull sales into hospitals, integrated delivery networks, and pain centers, cutting end-market concentration risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurodegenerative-disease positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBrainsWay’s mention of Alzheimer’s disease and Parkinson’s disease widens its scope beyond depression into longer-care neurology, where WHO says about 55 million people live with dementia and 8.5 million with Parkinson’s globally. That shifts the sales story from acute psychiatry clinics to chronic disease pathways. It also gives BrainsWay a broader TAM than its core depression use case.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRehabilitation-market participation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay’s move into rehabilitation-market participation can diversify demand beyond outpatient psychiatry, since post-stroke recovery and multiple sclerosis care sit in a different treatment channel. Stroke affects about 12.2 million people each year worldwide, and more than 2.8 million people live with MS globally, so rehab demand is large and recurring. Its non-invasive Deep TMS platform gives Company Name a practical base to reach rehab-focused clinics and hospitals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDifferent buyer set: rehab clinics and hospitals\u003c\/li\u003e\n\u003cli\u003eLarge need: stroke and MS patient pools\u003c\/li\u003e\n\u003cli\u003eLower reliance on psychiatry reimbursement cycles\u003c\/li\u003e\n\u003cli\u003eUses existing non-invasive neurostimulation know-how\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-vertical neuromodulation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBrainsWay Ltd. uses one Deep TMS base across mental health, neurology, pain, and rehab, so diversification is real business logic, not just a label. Its multi-indication portfolio already spans major depressive disorder, OCD, and smoking cessation, which reduces reliance on any single disease pool and supports cross-vertical sales from one installed platform.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne technology base\u003c\/li\u003e\n\u003cli\u003eMultiple therapy verticals\u003c\/li\u003e\n\u003cli\u003eLower disease-area dependence\u003c\/li\u003e\n\u003cli\u003eStronger cross-sell potential\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrainsWay Expands Deep TMS Into Pain and Neurology Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBrainsWay Ltd.’s diversification builds on one Deep TMS platform across psychiatry, neurology, pain, and rehab. That lowers reliance on depression alone and opens larger care pools, including 51 million U.S. adults with chronic pain, 55 million people with dementia, and 8.5 million with Parkinson’s globally.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePain\u003c\/td\u003e\n\u003ctd\u003e51M U.S. adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurology\u003c\/td\u003e\n\u003ctd\u003e55M dementia, 8.5M Parkinson’s\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234092491017,"sku":"bway-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bway-ansoff-matrix.webp?v=1785713885","url":"https:\/\/dcfanalyst.com\/products\/bway-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}